Apple Tree Partners is a venture capital firm in New York that invests in pharmaceuticals, biotech, medtech, and healthcare services. Founded 1999 in New York, United States, this firm invests in early stage ventures, late stage ventures and post-IPO rounds. Its portfolio companies include Limelight Bio, Chinook Therapeutics, Akero Therapeutics, Stoke Therapeutics, Corvidia, Braeburn, Stoke Therapeutics, Elstar Therapeutics, and Syntimmune. As of February 2020, Apple Tree Partners has made 37 investments. Their most recent investment was on Dec 5, 2019, when Limelight Bio raised $75M. Apple Tree Partners has had 11 exits, the most notable of which include Dermira, Aurinia Pharmaceuticals, and Aileron Therapeutics. The company has raised a single venture fund, Apple Tree Partners II - Annex, L.P.. This fund was announced on Nov 1, 2013 and raised a total of $13.5M.
Timeline
Funded Companies
Stoke Therapeutics is a biopharma company that develops RNA-targeted treatments for severe genetic diseases.
A medical device company developing transcatheter for mitral valve replacement and repair
A company that develops and commercializes therapies for prostate cancer and other hormonally-driven diseases
Chinook Therapeutics is a Seattle-based company founded in 2018.
Syntimmune is a Boston-based company.
People
Anna Batarina
Partner
Andreas Loew
Entrepreneur in Residence
Garry Neil
Adjunct Partner
Jonathan Waldstreicher
Principal
Martin Vogelbaum
Partner
Further reading
Documentaries, videos and podcasts
Companies
Akero Therapeutics
Braeburn
Chinook Therapeutics
Corvidia
Limelight Bio
Stoke Therapeutics